Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Director · President and CEO | December 04, 2023 | December 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date December 04, 2023 · Filed December 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 333,197 |
Ending reported balance
After 2023-12-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-12-04 · Exercise / conversion · Acquired 25,008 · Balance 358,205 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Row 2 · 2023-12-04 · Sale · Disposed 25,008 · Balance 333,197 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2023-12-05 · Exercise / conversion · Acquired 99,442 · Balance 432,639 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Row 4 · 2023-12-05 · Sale · Disposed 99,442 · Balance 333,197 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2024-11-11 | Direct | 184,522 |
Reported balance
After 2023-12-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-04 · Exercise / conversion · Disposed 25,008 · Balance 184,522 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4: This option is fully vested and exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2024-11-11 | Direct | 85,080 |
Reported balance
After 2023-12-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-05 · Exercise / conversion · Disposed 99,442 · Balance 85,080 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2023 Filed Dec 6, 2023 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 99,442 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-057600 · doc4.xml · derivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,080 Underlying: Common Stock · 99,442 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 99,442 | $5.17 | $514,115.14 |
DisclosureSEC source: 0001209191-23-057600 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 99,442 | $0.04 | $3,977.68 |
DisclosureSEC source: 0001209191-23-057600 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,008 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-057600 · doc4.xml · derivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,522 Underlying: Common Stock · 25,008 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 25,008 | $5.01 | $125,290.08 |
DisclosureSEC source: 0001209191-23-057600 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 25,008 | $0.04 | $1,000.32 |
DisclosureSEC source: 0001209191-23-057600 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 17:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,200 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-057093 · doc4.xml · derivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,530 Underlying: Common Stock · 20,200 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 17:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 20,200 | $5.00 | $101,000.00 |
DisclosureSEC source: 0001209191-23-057093 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 17:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 20,200 | $0.04 | $808.00 |
DisclosureSEC source: 0001209191-23-057093 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 17:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,350 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-057093 · doc4.xml · derivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,730 Underlying: Common Stock · 5,350 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 17:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,350 | $5.00 | $26,750.00 |
DisclosureSEC source: 0001209191-23-057093 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 17:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,350 | $0.04 | $214.00 |
DisclosureSEC source: 0001209191-23-057093 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,757 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · derivative · entry 9 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,080 Underlying: Common Stock · 16,757 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 16,757 | $5.02 | $84,120.14 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · nonDerivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 16,757 | $0.04 | $670.28 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · nonDerivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 349,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,798 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · derivative · entry 8 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251,837 Underlying: Common Stock · 12,798 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 12,798 | $5.04 | $64,501.92 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 12,798 | $0.04 | $511.92 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 445 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · derivative · entry 7 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,635 Underlying: Common Stock · 445 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 445 | $5.01 | $2,229.45 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.005 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 18:06 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 445 | $0.04 | $17.80 |
DisclosureSEC source: 0001209191-23-042110 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 28,883 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-037358 · doc4.xml · derivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,080 Underlying: Common Stock · 28,883 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 28,883 | $5.04 | $145,570.32 |
DisclosureSEC source: 0001209191-23-037358 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 28,883 | $0.04 | $1,155.32 |
DisclosureSEC source: 0001209191-23-037358 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,968 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-037358 · doc4.xml · derivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,963 Underlying: Common Stock · 14,968 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 14,968 | $5.03 | $75,289.04 |
DisclosureSEC source: 0001209191-23-037358 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 14,968 | $0.04 | $598.72 |
DisclosureSEC source: 0001209191-23-037358 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,149 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-027781 · doc4.xml · derivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,931 Underlying: Common Stock · 16,149 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 16,149 | $5.02 | $81,067.98 |
DisclosureSEC source: 0001209191-23-027781 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 16,149 | $0.04 | $645.96 |
DisclosureSEC source: 0001209191-23-027781 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 349,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 12, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,718 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · derivative · entry 9 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 325,080 Underlying: Common Stock · 12,718 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 12, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 12,718 | $5.00 | $63,590.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · nonDerivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.001, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 12, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 12,718 | $0.04 | $508.72 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · nonDerivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,182 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · derivative · entry 8 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,798 Underlying: Common Stock · 2,182 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 2,182 | $5.00 | $10,910.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 2,182 | $0.04 | $87.28 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 335,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · derivative · entry 7 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,980 Underlying: Common Stock · 100 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 100 | $5.00 | $500.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 16:37 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 100 | $0.04 | $4.00 |
DisclosureSEC source: 0001209191-23-024097 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 27,862 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-023806 · doc4.xml · derivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,080 Underlying: Common Stock · 27,862 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 27,862 | $5.03 | $140,145.86 |
DisclosureSEC source: 0001209191-23-023806 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 27,862 | $0.04 | $1,114.48 |
DisclosureSEC source: 0001209191-23-023806 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,961 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-023806 · doc4.xml · derivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 367,942 Underlying: Common Stock · 6,961 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 6,961 | $5.00 | $34,805.00 |
DisclosureSEC source: 0001209191-23-023806 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 6,961 | $0.04 | $278.44 |
DisclosureSEC source: 0001209191-23-023806 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,470 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · derivative · entry 9 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,903 Underlying: Common Stock · 7,470 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 7,470 | $5.03 | $37,574.10 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · nonDerivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 7,470 | $0.04 | $298.80 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · nonDerivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · derivative · entry 8 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,373 Underlying: Common Stock · 100 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 100 | $5.01 | $501.00 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.